Trial reportThe Journal of infectious diseases2020
Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach.
Trial report in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.The Journal of antimicrobial chemotherapy · 2024Trial
- Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk.Frontiers in immunology · 2021Trial
- Molecular insights in HIV-associated cardiac dysfunction.Communications medicine · 2025Article
- Forecasting off-target drug toxicity using proteomic and genetic data: insights from Torcetrapib.medRxiv : the preprint server for health sciences · 2025Article
- Cross-ethnic Molecular Signatures Underpin the Adverse Impact of Statin Use on Type 2 Diabetes.Genomics, proteomics & bioinformatics · 2025Article
- Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations.BMC cardiovascular disorders · 2025Review
- Using proteomics to identify the mechanisms underlying the benefits of statins on ischemic heart disease.NPJ cardiovascular health · 2024Article
- Statins-From Fungi to Pharmacy.International journal of molecular sciences · 2023Review
- Immune profiling in Puerto Rican injection drug users with and without HIV-1 infection.Journal of leukocyte biology · 2023Article
- High-throughput proteomic analysis reveals systemic dysregulation in virally suppressed people living with HIV.JCI insight · 2023Article
- A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study.Journal of proteomics · 2023Article
- Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy.The Journal of infectious diseases · 2022 · on this mapArticle
- Targeted plasma proteomics reveals upregulation of distinct inflammatory pathways in people living with HIV.iScience · 2022Article
- Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.Translational oncology · 2022Article
- Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment.Frontiers in cell and developmental biology · 2021Article
- Brief Report: Vascular Dysfunction and Monocyte Activation Among Women With HIV.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Profiling of Inflammatory Proteins in Plasma of HIV-1-Infected Children Receiving Antiretroviral Therapy.Proteomes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundPeople with human immunodeficiency virus (PWH) demonstrate increased atherosclerotic cardiovascular disease (ASCVD). Statins are being studied to prevent ASCVD in human immunodeficiency virus (HIV), but little is known regarding the effects of statins on a broad range of inflammatory and cardiovascular proteins in this population.
methodsWe used a highly specific discovery proteomic approach (Protein Extension Assay), to determine statin effects on over 350 plasma proteins in relevant ASCVD pathways among HIV and non-HIV groups. Responses to pitavastatin calcium were assessed in 89 PWH in the INTREPID trial and 46 non-HIV participants with features of central adiposity and insulin resistance. History of cardiovascular disease was exclusionary for both studies.
resultsAmong participants with HIV, PCOLCE (enzymatic cleavage of type I procollagen) significantly increased after pitavastatin therapy and PLA2G7 (systemic marker of arterial inflammation) decreased. Among participants without HIV, integrin subunit alpha M (integrin adhesive function) and defensin alpha-1 (neutrophil function) increased after pitavastatin therapy and PLA2G7 decreased. At baseline, comparing participants with and without HIV, differentially expressed proteins included proteins involved in platelet and endothelial function and immune activation.
conclusionsPitavastatin affected proteins important to platelet and endothelial function and immune activation, and effects differed to a degree within PWH and participants without HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.